EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma-Reference-Cited by-同舟云学术

EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma

Published:2020-12-03 Issue:1 Volume:13 Page:598-618
ISSN:1945-4589
Container-title:Aging
language:en
Short-container-title:Aging

Author:

Chen Zhiming¹,Chen Ji²,Ren Dandan³,Zhang Jiao³,Yang Ying³,Zhang Henghui⁴,Mao Beibei³,Ma Haitao¹

Affiliation:

1. Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China

2. Department of Thoracic Surgery, Huashan Hospital, Shanghai, China

3. Genecast Precision Medicine Technology Institute, Beijing, China

4. Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China

Publisher

Impact Journals, LLC

Subject

Cell Biology,Aging

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive analysis of Epha10 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in non-small cell lung cancer;Scientific Reports;2024-08-23

2. Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer;Journal of Translational Medicine;2024-06-18

3. A pan-cancer analysis of EphA family gene expression and its association with prognosis, tumor microenvironment, and therapeutic targets;Frontiers in Oncology;2024-06-17

4. Ephs in cancer progression: complexity and context-dependent nature in signaling, angiogenesis and immunity;Cell Communication and Signaling;2024-05-29

5. Constructing an APOBEC-related gene signature with predictive value in the overall survival and therapeutic sensitivity in lung adenocarcinoma;Heliyon;2023-11